Objective: To diagnose and determine the efficacy of medical therapy for laryngopharyngeal reflux according to RSI and RFS. Study design: Prospective study with intervention was designed for 38 patients Methods: Patients with RSI 13 and RFS 7 were enrolled and received esomeprazole 20mg twice daily in addition to lifestyle modification. The RSI and RFS were assessed at baseline, at the end of the 1 month, 2 month of treatment period and at week 4 of follow up period. Results: Among RSI items, the most common symptom was a globus sense in the throat (94.7 percent). Next, heartburn (86.8 percent), throat clearing (84.2 percent), excess throat mucus (84.2 percent), hoarseness (78.9 percent) were frequently reported. In RFS evaluation, the signs commonly detected were posterior commissure hypertrophy (100 percent), vocal cord edema (97.4 percent), diffuse laryngeal edema (94.7 percent), erythema (89.5 percent
). The authors observed pseudosulcus in 13.2 percent of patients. Initial RSI of the patients were ranging between 14 and 25 with a mean of 16.6 +/- 2.8. Posttreatment RSI were ranging between 1 and 11 with a mean of 4.8 +/- 2.6. The decrease in RSI was found to be highly statistically significant (p0.001). Similarly, total RFS decreased from 12.9 +/- 3.1 to 7.0 percent3.0 (p0.001). Conclusion: RSI, RFS are valuable tools in diagnosis and monitoring of LP R treatment. Thereby, PPI treatment (20mg, twice daily in 2 months) with lifestyle modification improve significantly laryngopharyngeal symptoms and signs due to reflux.